(Q34202181)

English

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

anti-retroviral agent

0 references

cerebrospinal fluid

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Scott L Letendre

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Anthony M Mills

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Karen T Tashima

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Deborah A Thomas

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sherene S Min

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Shuguang Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ivy H Song

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Stephen C Piscitelli

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

extended ING116070 study team

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

18 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1032-1037

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Therapeutic amprenavir concentrations in cerebrospinal fluid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Antiretroviral therapy and central nervous system HIV type 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

The role of blood-brain barrier studies in the pharmaceutical industry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4166983

5 July 2018

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU477

21 January 2018

CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24944232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIU477

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34202181&oldid=1561937963"